We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Vericel Corporation (VCEL - Free Report) shares rallied 16.3% in the last trading session to close at $27.73. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.1% gain over the past four weeks.
The company recently announced an accelerated launch timeline for MACI arthroscopic delivery, which is now anticipated to be launched in 2024 along with its preliminary results for the fourth quarter and full year 2022. Investors are also upbeat about the recent approval of NexoBrid.
This company is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -77.8%. Revenues are expected to be $52.6 million, up 10.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vericel Corporation, the consensus EPS estimate for the quarter has been revised 15.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VCEL going forward to see if this recent jump can turn into more strength down the road.
Vericel Corporation is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arbutus Biopharma (ABUS - Free Report) , finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month.
Arbutus' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.14. Compared to the company's year-ago EPS, this represents a change of +6.7%. Arbutus currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
Vericel Corporation (VCEL - Free Report) shares rallied 16.3% in the last trading session to close at $27.73. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.1% gain over the past four weeks.
The company recently announced an accelerated launch timeline for MACI arthroscopic delivery, which is now anticipated to be launched in 2024 along with its preliminary results for the fourth quarter and full year 2022. Investors are also upbeat about the recent approval of NexoBrid.
This company is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -77.8%. Revenues are expected to be $52.6 million, up 10.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vericel Corporation, the consensus EPS estimate for the quarter has been revised 15.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VCEL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Vericel Corporation is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arbutus Biopharma (ABUS - Free Report) , finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month.
Arbutus' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.14. Compared to the company's year-ago EPS, this represents a change of +6.7%. Arbutus currently boasts a Zacks Rank of #3 (Hold).